Vertex Pharmaceuticals
在场
是其中之一......
- Forbes Global 2000 (#553);
- Fortune 500 (#400);
- Nasdaq 100;
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Vertex Pharmaceuticals 是一家在股票代码 VRTX (US) 下上市的公司。
Vertex Pharmaceuticals 在 2 个国家有直接业务。
他们在：
涉及Vertex Pharmaceuticals的并购和融资。
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (公布2024四月16号).
高管
查看带有其 63 名主要高管的组织结构图
Vertex Pharmaceuticals 搜索最多的简介
- Reshma Kewalramani, Director, President and Chief Executive Officer
- Jeffrey Leiden, Executive Chairman of the Board
- Sangeeta Bhatia, Director
高管在Vertex Pharmaceuticals变化
- Jennifer Schneider已作为Director加入公司 (新闻发布的2024五月15号).
创建提醒
跟踪 Vertex Pharmaceuticals 的高管变动
生物技术
Vertex Pharmaceuticals 拥有 2,316 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Vertex Pharmaceuticals 的最新新闻稿
- Vertex Advances VX-548 in Acute and Neuropathic Pain | Vertex Pharmaceuticals Newsroom
- Vertex to Announce Second Quarter 2022 Financial Results on August 4 | Vertex Pharmaceuticals Newsroom
- Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes | Vertex Pharmaceuticals Newsroom
- Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes | Vertex Pharmaceuticals Newsroom
- Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress | Vertex Newsroom
- Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference | Vertex Newsroom
- Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15 | Vertex Newsroom
- Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA | Vertex Newsroom
- Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress | Vertex Newsroom
- Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference | Vertex Newsroom
- View more press releases Close
通过电子邮件
